{
  "catalogId": "78814886-f702-44cb-bf60-1663fe86d5d2",
  "name": "ONCOTICE",
  "status": "draft",
  "category": "29C",
  "registrationValidity": "valid",
  "registrationNumber": "103 18 28561 00",
  "treatmentDescriptions": "OncoTICE is used as a treatment of flat  urothelial cell carcinoma in situ (CIS) of the bladder and as an adjuvant therapy after transurethral resection (TUR) of a primary or relapsing superficial papillary urothelial cell carcinoma of the bladder stage Ta (grade 2 or 3) or T1 (grade 1 2 or 3).   OncoTICE is only recommended for stage Ta grade 1 papillary tumors  when there is judged to be a high risk of tumor recurrence.",
  "termsOfIssue": "",
  "form": "powder for solution for instillation",
  "route": "intra-vesically",
  "site": "",
  "method": "",
  "administrationNotes": "",
  "ingredients": "BCG STRAIN 200 - 800 MIU",
  "codes": {
    "atc5": {
      "system": "WHO ATC Classification",
      "code": "L03AX03",
      "name": "BCG VACCINE"
    }
  },
  "contraindications": "",
  "sideEffect": "",
  "warnings": "",
  "alternativeMedications": [],
  "packaging": [
    {
      "name": "BCG VACCINE SSI 0.75MG 10VIAL",
      "manufacturer": {
        "name": "",
        "countryOfOrigin": "IL"
      },
      "strength": {
        "value": 0,
        "unit": ""
      },
      "quantity": {
        "value": 10.0,
        "unit": "units"
      },
      "packagingDescription": "VIAL GLASS TYPE I",
      "shelfLife": "12",
      "storageConditions": "",
      "codes": {
        "moh": "20305",
        "barcode": "7290006537195"
      },
      "manufacturersAdministrationRecommendation": "",
      "pricing": {
        "currency": "ILS",
        "maxWholesalePrice": "",
        "retailMargin": "",
        "maxRetailPrice": "",
        "maxPriceWithVAT": ""
      }
    }
  ],
  "metadata": {
    "version": "1.4",
    "lastUpdated": "2025-08-01T12:18:43.617137"
  }
}